In summary, BCAT1 was one of the driving factors of carcinogenesis; and was a critical factor involved in the metabolic process of leukaemia growth and development; for the treatment of leukaemia, BCAT1 gene therapy can be targeted, such as BCAT1 inhibitors, BCAA-BCAT1-α-KG pathway target therapy for isocitrate dehydrogenase (IDH) Wilms Tumor (WT) TET2 WT AML patients with impaired leukaemia stem cell function, etc. These findings can broaden the treatment of leukaemia. The gene discussed is IDH3A; the disease is leukemia.